Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 2018

View Archived Issues

Merck & Co. identifies novel IDO-1 inhibitors

Processa Pharmaceuticals assigned license for CTP-499

DiscGenics studies IDCT in patients with symptomatic lumbar intervertebral disc degeneration

New phase II trial explores SAR-440340 alone and with dupilumab for moderate to severe asthma

SemaThera signs financing and licensing deal for ST-102

Zhejiang Hisun Pharmaceutical identifies new anti-HBV compounds

Discovery of novel potent BRAF inhibitor for the treatment of cancer

EMA reports negative CHMP assessment for abaloparatide-SC

Roche describes new TLR7 agonists and HBsAg secretion inhibitors

Novel PD-1/PD-L1 interaction inhibitors derived at Polaris Pharmaceuticals

Ohio State University, Georgia State University patent antiparasitic compounds

CARB-X and Shionogi partner to develop a novel antibiotic

OP-1074, a new candidate for ER-positive breast cancer

Soligenix receives E.U. orphan designation for RiVax

Argenx expands pipeline with ARGX-117 for autoimmune diseases

Lokelma receives E.U. approval for hyperkalemia

TSP5 linked to bladder cancer progression and survival

Galafold approved in Japan for Fabry disease

AZD-0364 demonstrates efficacy in preclinical models of NSCLC

EMA committee hands down positive opinion for Cabometyx

Ozempic approved in Japan

Japanese orphan drug designation awarded to gilteritinib for FLT3 mutation-positive AML

Dracen Pharmaceuticals receives investment for immuno-metabolism agents

Shingrix obtains approvals in E.U. and Japan

Annual Drugs to Watch report names 12 new potential blockbuster drugs

FDA expands Tasigna indications for pediatric patients with CML

vTv Therapeutics completes phase Ib of Simplici-T1 trial of TTP-399 in type 1 diabetes

CBT Pharmaceuticals licenses anti-CTLA-4 monoclonal antibody from Crown Bioscience

First preclinical data presented for VNRX-5133

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...